Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy

[1]  K. Ohta,et al.  A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. , 2004, Respiratory medicine.

[2]  Kazuo Komamura,et al.  Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  Patrick J Larson,et al.  An Evaluation of the Dose‐Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe , 2003, Journal of clinical pharmacology.

[4]  M. Ingelman-Sundberg,et al.  Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. , 2003, Molecular pharmacology.

[5]  T. Shimoda,et al.  Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma , 2003, Clinical pharmacology and therapeutics.

[6]  H. Yamazaki,et al.  A population phenotyping study of three drug‐metabolizing enzymes in Kyushu, Japan, with use of the caffeine test , 2002, Clinical pharmacology and therapeutics.

[7]  K. Kyvik,et al.  The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. , 2002, Pharmacogenetics.

[8]  H. Zhou,et al.  Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. , 2001, Pharmacogenetics.

[9]  P. Anzenbacher,et al.  Cytochromes P450 and metabolism of xenobiotics , 2001, Cellular and Molecular Life Sciences CMLS.

[10]  J. Yokota,et al.  Detection of Three Genetic Polymorphisms in the 5′‐Flanking Region and Intron 1 of Human CYP1A2 in the Japanese Population , 1999, Japanese journal of cancer research : Gann.

[11]  M. Aitkin,et al.  Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. , 1999, Pharmacogenetics.

[12]  J. Brockmöller,et al.  Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.

[13]  T. Kamataki,et al.  Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. , 1999, Journal of biochemistry.

[14]  K. Brøsen,et al.  Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. , 1997, British journal of clinical pharmacology.

[15]  K. Brøsen,et al.  Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. , 1996, Journal of chromatography. B, Biomedical applications.

[16]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[17]  T. Kamataki,et al.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  C. Page,et al.  Anti-inflammatory effects of low-dose oral theophylline in atopic asthma , 1994, The Lancet.

[19]  B. Tang,et al.  The use of caffeine for enzyme assays: A critical appraisal , 1993, Clinical pharmacology and therapeutics.

[20]  F. Gonzalez,et al.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.

[21]  U. Fuhr,et al.  Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. , 1992, Biochemical pharmacology.

[22]  L. Hendeles,et al.  A Clinical and Pharmacokinetic Basis for the Selection and Use of Slow Release Theophylline Products , 1984, Clinical pharmacokinetics.

[23]  C. Bierman.  Theophylline in asthma , 1976, Drug and therapeutics bulletin.

[24]  Y. Goto,et al.  Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. , 2005, Drug metabolism and pharmacokinetics.

[25]  P. Guzelian,et al.  Characterization of human liver cytochromes P-450 involved in theophylline metabolism. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[26]  T. Self,et al.  Theophylline toxicity: update. , 1990, Annals of allergy.

[27]  R. Dahlqvist,et al.  Theophylline--clinical pharmacokinetics and therapeutic drug monitoring. , 1984, European journal of respiratory diseases. Supplement.

[28]  Jacob Cohen.  CHAPTER 8 – F Tests on Means in the Analysis of Variance and Covariance , 1977 .